A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two important aspects. Dr. Acri’s whole paper is very good. I recommend you read it if you’re into policy and not sound bites. I noticed, however, that the comments on the article elicited some common myths about Canadian drug importation that are important to address if we’re going to really understand this issue.
Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- USPTO Responds to Patent Bar Gender Gap Inquiry, Mulls Changes to Registration Process
- How Patents Enable Mavericks and Challenge Incumbents
- ipAwarenessAssessment: Inventors and Business Owners Should Start Their IP Journey with this USPTO-NIST Tool
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles
Recent Posts
- USPTO Responds to Patent Bar Gender Gap Inquiry, Mulls Changes to Registration Process
- How Patents Enable Mavericks and Challenge Incumbents
- ipAwarenessAssessment: Inventors and Business Owners Should Start Their IP Journey with this USPTO-NIST Tool
- Other Barks & Bites for Friday, January 22: Iancu and Peter Step Down from USPTO, CJEU Asked Whether Preliminary Injunction Standard Burdens Patent Owners, SCOTUS Denial Leaves Invalidation of Idenix Genus Patent Claims Untouched
- US Inventor Backs SCOTUS Petition to Clarify Claim Construction Principles